GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
Roslin Institute · Western General Hospital · +423 more institutions
Abstract
Abstract Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown 1 to be highly efficient for discovery of genetic associations 2 . Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group 3 . Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a…
Citation impact
- FWCI
- 31.45
- Percentile
- 100%
- References
- 50
Authors
2642- EPErola Pairo‐CastineiraCorresponding
Roslin Institute, Western General Hospital, Centre for Inflammation Research, Institute of Genetics and Cancer, The Queen's Medical Research Institute, University of Edinburgh
- KRKonrad Rawlik
Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh
- ADAndrew D. Bretherick
Western General Hospital, NHS Tayside, Ninewells Hospital, Centre for Inflammation Research, Institute of Genetics and Cancer, The Queen's Medical Research Institute, University of Edinburgh
- TQTing Qi
Westlake University
- YWYang Wu
The University of Queensland
Topics & keywords
- Coronavirus disease 2019 (COVID-19)
- Genome-wide association study
- 2019-20 coronavirus outbreak
- Homogeneous
- Phenotype
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Genetic variants
- Meta-analysis
Funding
- WTWellcome TrustAward: 204979/Z/16/Z
- LLifeArc
- URUK Research and InnovationAwards: MC_PC_20029, MR/R026408/1
- NINational Institute for Health and Care Research
- BHBritish Heart Foundation
- DODepartment of Health and Social Care
- DUDiabetes UK
- RCResearch Councils UKAward: MR/R026408/1
- ECEuropean CommissionAwards: 204979, 34,35, COVID-19
- ICIntensive Care Society
- PHPublic Health England
- CNConselho Nacional de Desenvolvimento Científico e TecnológicoAward: 309173/2019-1
- NRNorthwest Regional Development Agency
- MRMedical Research CouncilAwards: MR/V001329/1, MC_UU_00007/15, MR/R026408/1, MR/R026408/1, MC_PC_20029, MC_PC_19025, MC_UU_00007/10, COVID-19, MRNO2995X/1
- BABiotechnology and Biological Sciences Research CouncilAwards: BBS/E/D/20002172, /30002275, BBS/E/RL/230002A, BBS/E/D/30002275, BBS/E/D/10002070
- IDInstituto de Salud Carlos IIIAwards: PI20/00876, COV20_00622
- EREuropean Regional Development Fund